Last reviewed · How we verify
ARRY-142886, MEK inhibitor; oral
ARRY-142886, MEK inhibitor; oral is a MEK inhibitor Small molecule drug developed by Array Biopharma, now a wholly owned subsidiary of Pfizer. It is currently in Phase 1 development for Solid tumors.
MEK inhibitor
MEK inhibitor Used for Solid tumors.
At a glance
| Generic name | ARRY-142886, MEK inhibitor; oral |
|---|---|
| Sponsor | Array Biopharma, now a wholly owned subsidiary of Pfizer |
| Drug class | MEK inhibitor |
| Target | MEK1 and MEK2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
ARRY-142886 is a potent and selective inhibitor of MEK1 and MEK2, enzymes that are key regulators of the MAPK/ERK signaling pathway.
Approved indications
- Solid tumors
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Fatigue
- Abdominal pain
Key clinical trials
- AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors (PHASE1, PHASE2)
- Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (PHASE3)
- MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PHASE2)
- AMTEC IIT: Phase 2 Multiarm Study in TNBC (PHASE2)
- A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) (PHASE1)
- Selumetinib and Azacitidine in High Risk Chronic Blood Cancers (PHASE1)
- A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer (PHASE2)
- Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARRY-142886, MEK inhibitor; oral CI brief — competitive landscape report
- ARRY-142886, MEK inhibitor; oral updates RSS · CI watch RSS
- Array Biopharma, now a wholly owned subsidiary of Pfizer portfolio CI
Frequently asked questions about ARRY-142886, MEK inhibitor; oral
What is ARRY-142886, MEK inhibitor; oral?
ARRY-142886, MEK inhibitor; oral is a MEK inhibitor drug developed by Array Biopharma, now a wholly owned subsidiary of Pfizer, indicated for Solid tumors.
How does ARRY-142886, MEK inhibitor; oral work?
MEK inhibitor
What is ARRY-142886, MEK inhibitor; oral used for?
ARRY-142886, MEK inhibitor; oral is indicated for Solid tumors.
Who makes ARRY-142886, MEK inhibitor; oral?
ARRY-142886, MEK inhibitor; oral is developed by Array Biopharma, now a wholly owned subsidiary of Pfizer (see full Array Biopharma, now a wholly owned subsidiary of Pfizer pipeline at /company/array-biopharma-now-a-wholly-owned-subsidiary-of-pfizer).
What drug class is ARRY-142886, MEK inhibitor; oral in?
ARRY-142886, MEK inhibitor; oral belongs to the MEK inhibitor class. See all MEK inhibitor drugs at /class/mek-inhibitor.
What development phase is ARRY-142886, MEK inhibitor; oral in?
ARRY-142886, MEK inhibitor; oral is in Phase 1.
What are the side effects of ARRY-142886, MEK inhibitor; oral?
Common side effects of ARRY-142886, MEK inhibitor; oral include Diarrhea, Nausea, Vomiting, Fatigue, Abdominal pain.
What does ARRY-142886, MEK inhibitor; oral target?
ARRY-142886, MEK inhibitor; oral targets MEK1 and MEK2 and is a MEK inhibitor.
Related
- Drug class: All MEK inhibitor drugs
- Target: All drugs targeting MEK1 and MEK2
- Manufacturer: Array Biopharma, now a wholly owned subsidiary of Pfizer — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Solid tumors
- Compare: ARRY-142886, MEK inhibitor; oral vs similar drugs
- Pricing: ARRY-142886, MEK inhibitor; oral cost, discount & access